(12) **PATENT** (11) Application No. AU 199936801 B2 **AUSTRALIAN PATENT OFFICE** (10) Patent No. 757965 (19) (54)Title 4,4-diarylbutadienes as water-soluble photostable UV filters for cosmetics and pharmaceutical preparations $(51)^{7}$ International Patent Classification(s) C07C 233/40 C07C 309/58 C07C 309/12 A61K 007/06 A61K 007/42 C07C 233/22 C07C 309/59 (21)Application No: 199936801 (22)Application Date: 1999.06.25 (30)Priority Data (31)Number (32) Date (33) Country 19828463 1998.06.26 DE (43)Publication Date: 2000.06.08 (43)Publication Journal Date: 2000.06.08 (44)Accepted Journal Date: 2003.03.13 (71)Applicant(s) **BASF Aktiengesellschaft** (72)Inventor(s) Thorsten Habeck; Horst Westenfelder; Thomas Wunsch (74)Agent/Attorney WATERMARK PATENT and TRADEMARK ATTORNEYS, Locked Bag 5, HAWTHORN VIC 3122

4,4-Diarylbutadienes as water-soluble, photostable UV filters for cosmetic and pharmaceutical preparations

5 Abstract

Use of 4,4-diarylbutadienes of the formula I,

10

$$(R^1)_n \xrightarrow{H} R^3$$

$$(R^2)_n$$

15

where the variables have the meanings explained in the description, as water-soluble photostable UV filters in cosmetic and pharmaceutical preparations for protecting the human skin or human hair from the sun's rays, alone or together with compounds which absorb in the UV region and are known per se for cosmetic and pharmaceutical preparations.

25

30

35

AUSTRALIA

Patents Act 1990

ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT

Application Number:

Lodged:

Invention Title:

4,4-DIARYLBUTADIENES AS WATER-SOLUBLE PHOTOSTABLE UV FILTERS FOR COSMETIC AND PHARMACEUTICAL PREPARATIONS

The following statement is a full description of this invention, including the best method of performing it known to us :-

4,4-Diarylbutadienes as water-soluble photostable UV filters for cosmetic and pharmaceutical preparations

The invention relates to the use of 4,4-diarylbutadienes as water-soluble photostable UV filters in cosmetic and pharmaceutical preparations for protecting the human epidermis or human hair from UV radiation, specifically in the range from 320 10 to 400 nm

The sunscreens employed in cosmetic and pharmaceutical preparations have the task of preventing, or at least diminishing the consequences of, harmful effects of sunlight on the human 15 skin. However, these sunscreens also serve to protect other ingredients from decomposition or breakdown by UV radiation. In hair cosmetic formulations the aim is to reduce damage to the keratin fibers by UV rays.

20 The sunlight reaching the surface of the earth contains UV-B radiation (280 to 320 nm) and UV-A radiation (> 320 nm), which are directly adjacent to the visible light region. The effect on the human skin is manifested, particularly in the case of UV-B radiation, by sunburn. Accordingly, the industry offers a 25 relatively large number of substances which absorb UV-B radiation and thus prevent sunburn.

Dermatoglogical investigations have now shown that UV-A radiation is also perfectly capable of causing skin damage and allergies $^{\mathbf{30}}$ by, for example, damaging the keratin or elastin. This reduces the elasticity and water storage capacity of the skin, i.e. the skin becomes less supple and tends to form wrinkles. The noticeably high incidence of skin cancer in regions where the sun's radiation is strong shows that damage to the genetic 35 information in the cells is evidently also caused by sunlight, specifically by UV-A radiation. All these findings therefore make it appear necessary to develop efficient filter substances for the UV-A region.

40 There is a growing demand for sunscreens for cosmetic and pharmaceutical preparations which can be used in particular as UV-A filters and whose absorption maxima ought therefore to be in the range from about 320 to 380 nm. In order to achieve the required effect by using the minimum amount, sunscreens of this type ought additionally to have a high specific extinction. Sunscreens for certain cosmetic products must also meet a large number of other requirements, for example good solubility in

water or in water-miscible solvents, such as alcohols, high stability of the solutions or emulsions produced with them, toxicological acceptability, and slight intrinsic odor and slight intrinsic color.

5

Another requirement which sunscreens must meet is adequate photostability. However, this is only inadequately ensured, if at all, with the UV-A-absorbing sunscreens hitherto available.

10 French Patent No. 2 440 933 describes 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethane as a UV-A filter. It is proposed to combine this specific UV-A filter, which is sold by GIVAUDAN under the name "PARSOL 1789", with various UV-B filters in order to absorb all UV rays having a wavelength from 280 to 380 nm.

However, this UV-A filter does not have sufficient photochemical stability, when used alone or in combination with UV-B filters, to ensure sustained protection of the skin during sunbathing for 20 prolonged periods, which means that repeated applications at regular and short intervals are required if effective protection of the skin from all UV rays is desired.

For this reason, EP-A-0 514 491 discloses the stabilization of 25 the insufficiently photostable UV-A filters by adding 2-cyano-3,3-diphenylacrylic esters which themselves act as filters in the UV-B region.

It has furthermore already been proposed in EP-A-0 251 398 to 30 combine chromophores absorbing UV-A radiation and UV-B radiation into one molecule by using a linker. This has the disadvantage that, firstly a free combination of UV-A and UV-B filters in the cosmetic preparation is no longer possible, and that difficulties in the chemical linkage of the chromophores allow only certain 35 combinations.

US 4,950,467 describes the use of 2,4-pentadienoic acid derivatives as UV absorbers in cosmetic products. The monoaryl-substituted compounds which are mentioned as preferred in this patent likewise have the disadvantage that their photostability is insufficient.

It is an object of the present invention to propose sunscreens 45 for cosmetic and pharmaceutical purposes which absorb in the UV-A region with high extinction, are photostable, have a slight

intrinsic color, i.e. a sharp band structure, and are readily soluble in water or in water-miscible solvents.

This object is achieved according to the invention by use of 5 4,4-diarylbutadienes of the formula I

- where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:
- 20 R^1 and R^2

hydrogen, C_1 - C_{20} -alkyl, C_2 - C_{10} -alkenyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkenyl, C_1 - C_{12} -alkoxy, C_1 - C_{20} -alkoxycarbonyl, C_1 - C_{12} -alkylamino, C_1 - C_{12} -dialkylamino, aryl, hetaryl, unsubstituted or substituted substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

 R^3 hydrogen, COOR⁵, COR⁵, CONR⁵R⁶, CN;

R⁴ COOR⁶, COR⁶, CONR⁵R⁶;

 R^5 hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene- SO_3Y , C_1-C_6 -alkylene- PO_3Y , C_1-C_6 -alkylene- $N(R^8)_3$ + A-;

 R^6 [X]_o- R^7 , C_1 - C_6 -alkylene- SO_3 Y, C_1 - C_6 -alkylene- PO_3 Y, C_1 - C_6 -alkylene- $N(R^8)_3$ + A^- ;

40 x $-CH_2-CH_2-Z-$, $-CH_2-CH_2-CH_2-Z-$, $-CH(CH_3)-CH_2-Z-$, $-CH_2-CH_2-CH_2-CH_2-Z-$, $-CH_2-CH(CH_2-CH_3)-Z-$;

A C1, Br, I, SO_4R^9 ;

45 Y hydrogen, Na⁺, K⁺, Mg²⁺, Ca²⁺, Li⁺, Al³⁺, N(R⁸)₄⁺;

1 to 150

4

- as water-soluble photostable UV filters in cosmetic and
 pharmaceutical preparations for protecting the human skin or
 human hair from the sun's rays, alone or together with compounds
 which absorb in the UV region and are known per se for cosmetic
 and pharmaceutical preparations.
- Alkyl radicals R¹ and R² which may be mentioned are branched or unbranched C₁-C₂₀-alkyl chains, preferably methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl,
- 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl,
- 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl,
 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl,
 1-ethyl-2-methylpropyl, n-heptyl, n-octyl, n-nonyl, n-decyl,
 n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl,
 n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl or n-eicosyl.
- Alkenyl radicals R¹ and R² which may be mentioned are branched or unbranched C₂-C₁₀-alkenyl chains, preferably vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 2-methyl-1-butenyl, 2-methyl-2-butenyl, 3-methyl-1-butenyl, 1-hexenyl, 1-hexenyl, 1-heptenyl, 2-heptenyl, 1-octenyl or 2-octenyl.

Cycloalkyl radicals which may be mentioned for R¹ and R² are preferably branched or unbranched C₃-C₁₀-cycloalkyl radicals such 45 as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-methylcyclopropyl, 1-ethylcyclopropyl, 1-propylcyclopropyl, 1-butylcyclopropyl, 1-pentylcyclopropyl,

1-methyl-1-butylcyclopropyl, 1,2-dimethylcyclopropyl, 1-methyl-2-ethylcyclopropyl, cyclooctyl, cyclononyl or cyclodecyl.

- 5 Cycloalkenyl radicals which may be mentioned for R¹ and R² are preferably branched or unbranched C₃-C₁₀-cycloalkenyl radicals with one or more double bonds such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptenyl, cycloheptatrienyl, cyclooctenyl, 1,5-cyclooctadienyl, cyclooctatetraenyl, cyclononenyl or cyclodecenyl.
- The cycloalkenyl and cycloalkyl radicals may be unsubstituted or substituted by one or more, e.g. 1 to 3, radicals such as halogen, e.g. fluorine, chlorine or bromine, cyano, nitro, amino, C_1-C_4 -alkylamino, C_1-C_4 -dialkylamino, hydroxyl, C_1-C_4 -alkyl, C_1-C_4 -alkoxy or other radicals, or contain 1 to 3 heteroatoms such as sulfur, nitrogen, whose free valencies can be saturated by hydrogen or C_1-C_4 -alkyl, or oxygen in the ring.

Suitable alkoxy radicals for \mathbb{R}^1 and \mathbb{R}^2 are those having 1 to 12 carbon atoms, preferably having 1 to 8 carbon atoms.

25 Examples which may be mentioned are:

methoxy ethoxy isopropoxy n-propoxy 1-methylpropoxy n-butoxy 30 n-pentoxy 2-methylpropoxy 3-methylbutoxy 1,1-dimethylpropoxy 2,2-dimethylpropoxy hexoxy 1-methyl-1-ethylpropoxy heptoxy octoxy 2-ethylhexoxy 35

Examples of alkoxycarbonyl radicals for \mbox{R}^{1} and \mbox{R}^{2} are esters containing the abovementioned alkoxy radicals or radicals derived from higher alcohols, e.g. having up to 20 carbon atoms, such as iso- C_{15} alcohol.

Suitable mono- or dialkylamino radicals for R¹ and R² are those containing alkyl radicals having 1 to 12 carbon atoms, such as methyl, n-propyl, n-butyl, 2-methylpropyl, 1,1-dimethylpropyl, 45 hexyl, heptyl, 2-ethylhexyl, isopropyl, 1-methylpropyl, n-pentyl,

3-methylbutyl, 2,2-dimethylpropyl, 1-methyl-1-ethylpropyl and octyl.

Aryl means aromatic rings or ring systems having 6 to 18 carbon 5 atoms in the ring system, for example phenyl or naphthyl, each of which may be unsubstituted or substituted by one or more radicals such as halogen, e.g. fluorine, chlorine or bromine, cyano, nitro, amino, C_1 - C_4 -alkylamino, C_1 - C_4 -dialkylamino, hydroxyl, C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy or other radicals. Unsubstituted or 10 substituted phenyl, methoxyphenyl and naphthyl are preferred.

Hetaryl radicals are advantageously simple or fused aromatic ring systems having one or more heteroaromatic 3- to 7-membered rings. Heteroatoms which may be present in the ring or ring system are one or more nitrogen, sulfur and/or oxygen atoms.

Hydrophilic radicals, i.e. those making it possible for the compounds of the formula I to dissolve in water, for R¹ and R² are, for example, carboxyl and sulfoxy radicals and, in particular, their salts with any physiologically tolerated cations, such as the alkali metal salts or such as the trialkylammonium salts, such as tri(hydroxyalkyl)ammonium salts or the 2-methyl-1-propanol-2-ammonium salts. Also suitable are ammonium radicals, especially alkylammonium radicals, with any physiologically tolerated anions.

Alkylene groups for R^5 and R^6 which carry hydrophilic SO_3Y , PO_3Y or $N(R^8)_3^+A^-$ radicals which may be mentioned are branched or unbranched C_1-C_6 -alkylene radicals, preferably methylene, ethylene, n-propylene, 1-methylethylene, n-butylene, 1-methylpropylene, 2-methylpropylene, n-pentylene or n-hexylene.

The radical [X]₀-R⁷ for R⁵ and R⁶ is, inter alia, polyalkylene glycols which may comprise from 1 to 150 monomer units, preferably from 1 to 50, particularly preferably from 1 to 30, monomer units. X may be an alkylene glycol monomer unit selected from the group consisting of ethylene glycol, n-propylene glycol, 1-methylethylene glycol, n-butylene glycol and 1-ethylethylene glycol. Preferred monomer units may be ethylene glycol, n-propylene glycol and 1-methylethylene glycol.

The polyalkylene glycols may be terminally alkylated, alkenylated or acylated.

O.Z. 0050/49162

Alkyl radicals for R^7 to R^9 which may be mentioned are branched or unbranched $C_1 - C_6 - alkyl$ chains, preferably methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 5 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl,

10 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl or 1-ethyl-2-methylpropyl.

Alkenyl radicals for R⁷ to R⁹ which may be mentioned are branched 15 or unbranched C2-C6-alkenyl chains, preferably vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 2-methyl-1-butenyl, 2-methyl-2-butenyl, 3-methyl-1-butenyl, 1-hexenyl or 2-hexenyl.

20 Acyl radicals for R^7 and R^8 which may be mentioned are C_1-C_6 -acyl radicals, preferably formyl, acetyl, propionyl or n-butyryl.

Also suitable for $[X]_0-R^7$ are polyalkylenepolyamines, in particular polyethyleneimines which may likewise comprise 1 to 25 150 monomer units, preferably 1 to 50, particularly preferably 1 to 30 monomer units.

Preferred compounds of the formula I are those where

30 R^1 and R^2

are, independently of one another, hydrogen, C_1 - C_8 -alkyl, C_1-C_8 -alkoxy, C_1-C_8 -alkylamino, C_1-C_8 -dialkylamino, substituents which confer solubility in water and are selected from 35 the group consisting of carboxylate, sulfonate or ammonium radicals;

 \mathbb{R}^3 is COOR⁵, CONR⁵R⁶, CN;

40

 R^4 is COOR6, CONR5R6;

R⁵ is hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene- SO_3Y , C_1-C_6 -alkylene- $N(R^8)_3 + A^-;$ 45

 R^6 is $[X]_0-R^7$, C_1-C_6 -alkylene- SO_3Y , C_1-C_6 -alkylene- $N(R^8)_3+A^-$;

 $X is -CH_2-CH_2-O-, -CH_2-CH_2-CH_2-O-, -CH(CH_3)-CH_2-O-;$

A is Cl, Br, I, SO₄R⁹;

Y is hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;

10 R^7 and R^9

are hydrogen, C_1-C_3 -alkyl;

15 ⁿ is 1 to 3;

o is 1 to 50.

 C_1-C_8 -Alkyl radicals which are particularly preferred for R^1 and 20 R^6 are methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 2-ethylhexyl.

25 Suitable alkoxy radicals for R^1 and R^2 are, preferably, those having 1 to 8 carbon atoms, and particularly preferably those having 1 to 4 carbon atoms.

Examples which may be mentioned are:

30

methoxy

ethoxy

isopropoxy

n-propoxy

n-butoxy

1-methylpropoxy

2-methylpropoxy

Suitable and particularly preferred mono- or dialkylamino radicals for R^1 and R^2 are methyl, ethyl, n-propyl, n-butyl, 2-methylpropyl, 1,1-dimethylpropyl, 2-ethylhexyl.

40

Particularly preferred C_1 - C_3 -alkyl radicals for R^7 to R^9 which may be mentioned are methyl, ethyl, n-propyl or isopropyl.

Particularly preferred alkylene groups for R⁵ and R⁶, which carry hydrophilic SO₃Y, PO₃Y or N(R⁸)₃+A⁻ radicals, which may be mentioned are methylene, ethylene, n-propylene, 1-methylethylene or n-butylene.

5

The substituents R^1 and R^2 may each be bonded to the aromatic ring in the ortho, meta and/or para position. In the case of disubstituted aromatic rings (n = 2), R^1 and R^2 can be in the ortho/para or meta/para position. Preferred compounds of the 10 formula I where n=1 are those where R^1 is identical to R^2 and both radicals are in the para position.

Furthermore, compounds of the formula I(n = 1) in which the substituents R^1 to R^4 are present in the combination given in Table 1 have particular photostable properties:

Table 1:

20

25

$$(R^1)_n$$
 H
 R^3
 R^4
 $(R^2)_n$
 $n=1$

| R^1 | R ² | Position | R ³ | R ⁴ |
|--|---|---------------------------------------|---------------------------------------|---------------------------------------|
| Н | Н | | Н | COR ⁶ |
| Н | Н | | Н | CONR ⁵ R ⁶ |
| Н | Н | | COOR ⁵ | COOR ⁶ |
| Н | Н | | COOR ⁵ | COR ⁶ |
| Н | Н | | COR ⁵ | COR ⁶ |
| Н | Н | | CONR ⁵ R ⁶ | COOR ⁶ |
| Н | Н | | CONR ⁵ R ⁶ | COR ⁶ |
| Н | Н | | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| Н | Н | | CN | COR ⁶ |
| Н | Н | | CN | CONR ⁵ R ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | Н | COR ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | Н | COR ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | Н | COR ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | Н | CONR ⁵ R ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | H | CONR ⁵ R ⁶ |
| C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | Н | CONR ⁵ R ⁶ |
| | H H H H H H H H C ₁ -C ₈ -Alkoxy | H H H H H H H H H H H H H H H H H H H | H H H H H H H H H H H H H H H H H H H | H H H H H H H H H H H H H H H H H H H |

| | | | | | |
|-----|--|--|----------|----------------------------------|----------------------------------|
| | R ¹ | R ² | Position | R ³ | R ⁴ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | COOR ⁵ | COOR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | COOR ⁵ | COOR ⁶ |
| 5 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | COOR ⁵ | COOR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | COOR ⁵ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | COOR ⁵ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | COOR ⁵ | COR ⁶ |
| 10 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | COR ⁵ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | COR ⁵ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | COR ⁵ | COR6 |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | CONR ⁵ R ⁶ | COOR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | CONR ⁵ R ⁶ | COOR ⁶ |
| 15 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | CONR ⁵ R ⁶ | COOR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | CONR ⁵ R ⁶ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | CONR ⁵ R ⁶ | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | CONR ⁵ R ⁶ | COR ⁶ |
| 20 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| 25 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | CN | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | CN | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | CN | COR ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | para | CN | CONR ⁵ R ⁶ |
| | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | ortho | CN | CONR ⁵ R ⁶ |
| 2.0 | C ₁ -C ₈ -Alkoxy | C ₁ -C ₈ -Alkoxy | meta | CN | CONR ⁵ R ⁶ |
| 30 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | Н | COR ⁶ |
| | C_1 - C_{12} -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | Н | COR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | Н | COR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | Н | CONR ⁵ R ⁶ |
| 35 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | Н | CONR ⁵ R ⁶ |
| | C_1 - C_{12} -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | Н | CONR ⁵ R ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | COOR ⁵ | COOR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | COOR ⁵ | COOR ⁶ |
| 40 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | COOR ⁵ | COOR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | COOR ⁵ | COR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C_1 - C_{12} -Alkyl | ortho | COOR ⁵ | COR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | COOR ⁵ | COR ⁶ |
| 45 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | COR ⁵ | COR ⁶ |
| 30 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | COR ⁵ | COR ⁶ |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | COR ⁵ | COR ⁶ |
| | | | | | |

| | ±± | | | | | | |
|------------|--|--|----------|----------------------------------|----------------------------------|--|--|
| | R ¹ | R ² | Position | R ³ | R ⁴ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | CONR ⁵ R ⁶ | COOR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | CONR ⁵ R ⁶ | COOR ⁶ | | |
| 5 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | CONR ⁵ R ⁶ | COOR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | CONR ⁵ R ⁶ | COR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | CONR ⁵ R ⁶ | COR ⁶ | | |
| 10 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | CONR ⁵ R ⁶ | COR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |
| 10 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | CN | COR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | CN | COR ⁶ | | |
| 15 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | CN | COR ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | para | CN | CONR ⁵ R ⁶ | | |
| | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | ortho | CN | CONR ⁵ R ⁶ | | |
| 20 | C ₁ -C ₁₂ -Alkyl | C ₁ -C ₁₂ -Alkyl | meta | CN | CONR ⁵ R ⁶ | | |
| | Carboxylate | Carboxylate | para | Н | COR ⁶ | | |
| | Carboxylate | Carboxylate | ortho | Н | COR ⁶ | | |
| | Carboxylate | Carboxylate | meta | Н | COR ⁶ | | |
| | Carboxylate | Carboxylate | para | Н | CONR ⁵ R ⁶ | | |
| 25 | Carboxylate | Carboxylate | ortho | Н | CONR ⁵ R ⁶ | | |
| ⊿ 5 | Carboxylate | Carboxylate | meta | Н | CONR ⁵ R ⁶ | | |
| | Carboxylate | Carboxylate | para | COOR ⁵ | COOR ⁶ | | |
| | Carboxylate | Carboxylate | ortho | COOR ⁵ | COOR ⁶ | | |
| 20 | Carboxylate | Carboxylate | meta | COOR ⁵ | COOR ⁶ | | |
| 30 | Carboxylate | Carboxylate | para | COOR ⁵ | COR ⁶ | | |
| | Carboxylate | Carboxylate | ortho . | COOR ⁵ | COR ⁶ | | |
| | Carboxylate | Carboxylate | meta | COOR ⁵ | COR ⁶ | | |
| | Carboxylate | Carboxylate | para | COR ⁵ | COR ⁶ | | |
| 35 | Carboxylate | Carboxylate | ortho | COR ⁵ | COR ⁶ | | |
| | Carboxylate | Carboxylate | meta | COR ⁵ | COR ⁶ | | |
| | Carboxylate | Carboxylate | para | CONR ⁵ R ⁶ | COOR ⁶ | | |
| | Carboxylate | Carboxylate | ortho | CONR ⁵ R ⁶ | COOR ⁶ | | |
| 40 | Carboxylate | Carboxylate | meta | CONR ⁵ R ⁶ | COOR ⁶ | | |
| 40 | Carboxylate | Carboxylate | para | CONR ⁵ R ⁶ | COR ⁶ | | |
| | Carboxylate | Carboxylate | ortho | CONR ⁵ R ⁶ | COR ⁶ | | |
| | Carboxylate | Carboxylate | meta | CONR ⁵ R ⁶ | COR ⁶ | | |
| 45 | Carboxylate | Carboxylate | para | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |
| | Carboxylate | Carboxylate | ortho | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |
| | Carboxylate | Carboxylate | meta | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | | |

| | 12 | | | | | |
|----|----------------|----------------|----------|----------------------------------|----------------------------------|--|
| | R ¹ | R ² | Position | R ³ | R ⁴ | |
| | Carboxylate | Carboxylate | para | CN | COR ⁶ | |
| | Carboxylate | Carboxylate | ortho | CN | COR ⁶ | |
| 5 | Carboxylate | Carboxylate | meta | CN | COR ⁶ | |
| | Carboxylate | Carboxylate | para | CN | CONR ⁵ R ⁶ | |
| | Carboxylate | Carboxylate | ortho | CN | CONR ⁵ R ⁶ | |
| | Carboxylate | Carboxylate | meta | CN | CONR ⁵ R ⁶ | |
| 10 | Sulfonate | Sulfonate | para | н | COR ⁶ | |
| 10 | Sulfonate | Sulfonate | ortho | Н | COR ⁶ | |
| | Sulfonate | Sulfonate | meta | Н | COR ⁶ | |
| | Sulfonate | Sulfonate | para | н | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | ortho | Н | CONR ⁵ R ⁶ | |
| 15 | Sulfonate | Sulfonate | meta | Н | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | para | COOR5 | COOR ⁶ | |
| | Sulfonate | Sulfonate | ortho | COOR5 | COOR ⁶ | |
| | Sulfonate | Sulfonate | meta | COOR ⁵ | COOR ⁶ | |
| 20 | Sulfonate | Sulfonate | para | COOR5 | COR ⁶ | |
| | Sulfonate | Sulfonate | ortho | COOR ⁵ | COR ⁶ | |
| 25 | Sulfonate | Sulfonate | meta | COOR ⁵ | COR ⁶ | |
| | Sulfonate | Sulfonate | para | COR ⁵ | COR ⁶ | |
| | Sulfonate | Sulfonate | ortho | COR ⁵ | COR ⁶ | |
| | Sulfonate | Sulfonate | meta | COR ⁵ | COR ⁶ | |
| | Sulfonate | Sulfonate | para | CONR ⁵ R ⁶ | COOR ⁶ | |
| | Sulfonate | Sulfonate | ortho | CONR ⁵ R ⁶ | COOR ⁶ | |
| 30 | Sulfonate | Sulfonate | meta | CONR ⁵ R ⁶ | COOR ⁶ | |
| 30 | Sulfonate | Sulfonate | para | CONR ⁵ R ⁶ | COR ⁶ | |
| | Sulfonate | Sulfonate | ortho | CONR ⁵ R ⁶ | COR ⁶ | |
| | Sulfonate | Sulfonate | meta | CONR ⁵ R ⁶ | COR ⁶ | |
| | Sulfonate | Sulfonate | para | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | |
| 35 | Sulfonate | Sulfonate | ortho | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | meta | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | para | CN | COR ⁶ | |
| | Sulfonate | Sulfonate | ortho | CN | COR ⁶ | |
| 40 | Sulfonate | Sulfonate | meta | CN | COR ⁶ | |
| | Sulfonate | Sulfonate | para | CN | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | ortho | CN | CONR ⁵ R ⁶ | |
| | Sulfonate | Sulfonate | meta | CN | CONR ⁵ R ⁶ | |
| 45 | Ammonium | Ammonium | para | Н | COR6 | |
| | Ammonium | Ammonium | ortho | Н | COR ⁶ | |
| | Ammonium | Ammonium | meta | н | COR ⁶ | |

| | R^1 | R ² | Position | R ³ | R ⁴ |
|----------------|----------|----------------|----------|----------------------------------|----------------------------------|
| | Ammonium | Ammonium | para | Н | CONR ⁵ R ⁶ |
| 5 | Ammonium | Ammonium | ortho | Н | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | meta | Н | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | para | COOR ⁵ | COOR ⁶ |
| | Ammonium | Ammonium | ortho | COOR ⁵ | COOR ⁶ |
| | Ammonium | Ammonium | meta | COOR ⁵ | COOR6 |
| 10 | Ammonium | Ammonium | para | COOR ⁵ | COR ⁶ |
| 10 | Ammonium | Ammonium | ortho . | COOR ⁵ | COR ⁶ |
| | Ammonium | Ammonium | meta | COOR ⁵ | COR ⁶ |
| | Ammonium | Ammonium | para | COR ⁵ | COR ⁶ |
| | Ammonium | Ammonium | ortho | COR ⁵ | COR ⁶ |
| 15 | Ammonium | Ammonium | meta | COR ⁵ | COR ⁶ |
| | Ammonium | Ammonium | para | CONR ⁵ R ⁶ | COOR ⁶ |
| | Ammonium | Ammonium | ortho | CONR ⁵ R ⁶ | COOR ⁶ |
| | Ammonium | Ammonium | meta | CONR ⁵ R ⁶ | COOR ⁶ |
| 20 | Ammonium | Ammonium | para | CONR ⁵ R ⁶ | COR ⁶ |
| | Ammonium | Ammonium | ortho | CONR ⁵ R ⁶ | COR ⁶ |
| 15 20 25 | Ammonium | Ammonium | meta | CONR ⁵ R ⁶ | COR ⁶ |
| | Ammonium | Ammonium | para | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| 25 | Ammonium | Ammonium | ortho | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | meta | CONR ⁵ R ⁶ | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | para | CN | COR ⁶ |
| | Ammonium | Ammonium | ortho | CN | COR ⁶ |
| 2.0 | Ammonium | Ammonium | meta | CN | COR ⁶ |
| 30 | Ammonium | Ammonium | para | CN | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | ortho | CN | CONR ⁵ R ⁶ |
| | Ammonium | Ammonium | meta | CN | CONR ⁵ R ⁶ |

The invention also relates to 4,4-diarylbutadienes of the formula I,

5

10

$$(R^1)_n$$
 H
 R^3
 $(R^2)_n$

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

 R^1 and R^2

hydrogen, C_1 - C_{20} -alkyl, C_2 - C_{10} -alkenyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkenyl, C_1 - C_{12} -alkoxy, C_1 - C_{20} -alkoxycarbonyl, C_1 - C_{12} -alkylamino, C_1 - C_{12} -dialkylamino, aryl, hetaryl, unsubstituted or substituted substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

25

- R³ hydrogen, COOR⁵, COR⁵, CONR⁵R⁶, CN;
- R⁴ COOR⁶, COR⁶, CONR⁵R⁶;

30

- R⁵ hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-PO₃Y, C_1-C_6 -alkylene-N(R⁸)₃+ A⁻;
- 35 $R^6 = [X]_o R^7$, $C_1 C_6 alkylene SO_3Y$, $C_1 C_6 alkylene PO_3Y$, C_1

- A C1, Br, I, SO₄R⁹;
- Y hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;
- 45 Z O, NH;

 R^7 and R^8

hydrogen, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_1 - C_6 -acyl;

⁵ R⁹ hydrogen, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl;

n 1 to 3;

10 0 1 to 150.

Preference is given to 4,4-diarylbutadienes of the formula Ia,

15 (R¹)_n H R³ R⁴ Ia

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

 R^1 and R^2

hydrogen, C₁-C₈-alkyl, C₁-C₈-alkoxy, 30 substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

R³ COOR⁵, CONR⁵R⁶, CN;

R4 COOR6, CONR5R6;

 R^5 hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-N(R^8)₃+40 A^- ;

 R^6 [X] $_{0}$ - R^7 , C_1 - C_6 -alkylene-SO₃Y, C_1 - C_6 -alkylene-N(R^8) $_{3}$ + A⁻;

 $X = -CH_2-CH_2-O-, -CH_2-CH_2-CH_2-O-, -CH(CH_3)-CH_2-O-;$ 45

A Cl, Br, I, SO_4R^9 ;

Y hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;

 R^7 to R^9

5 hydrogen, C₁-C₃-alkyl;

n 1 to 3;

10 0 1 to 50.

Particular preference is given to 4,4-diarylbutadienes of the formula Ib,

15

$$R^1$$
 R^2
 H
 R^3
 R^4
Ib

20

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

 R^1 and R^2

30

hydrogen, C_1 - C_8 -alkyl, C_1 - C_8 -alkoxy;

R³ COOR⁵, CONR⁵R⁶, CN;

 R^4 COOR⁶, CONR⁵R⁶;

R⁵ hydrogen, [X] $_{o}$ -R⁷, C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R⁸) $_{3}$ + A⁻;

40

 R^6 [X] $_{o}$ - R^7 , C_1 - C_6 -alkylene- SO_3 Y, C_1 - C_6 -alkylene- $N(R^8)_3$ + A-;

 $X - CH_2 - CH_2 - O-, -CH_2 - CH_2 - CH_2 - O-, -CH(CH_3) - CH_2 - O-;$

45 A Cl, Br, I, SO₄R⁹;

Y hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;

 ${\rm R}^7$ to ${\rm R}^9$

5 hydrogen, C_1-C_3 -alkyl;

o 1 to 50.

10 Very particular preference is given to 4,4-diarylbutadienes of the formula Ic,

15
$$\begin{array}{c} R^1 \\ H \\ R^4 \end{array}$$
 Ic

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration
or a mixture thereof, and where the variables independently of
one another have the following meanings:

 R^1 and R^2

30 hydrogen, C_1 - C_8 -alkyl, C_1 - C_8 -alkoxy;

 R^3 COOR⁵, CONR⁵R⁶, CN;

35 R4 COOR6, CONR5R6;

R⁵ hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-N(R⁸)₃+A⁻;

40 R^6 [X] $_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-N(R^8) $_3$ + A⁻;

 $X - CH_2 - CH_2 - O-, -CH_2 - CH_2 - CH_2 - O-, -CH(CH_3) - CH_2 - O-;$

45 A C1, Br, I, SO₄R⁹;

Y hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;

 R^7 to R^9

- 5 hydrogen, C_1 - C_3 -alkyl;
 - o 1 to 50.
- 10 The more accurate definition of the substituents R^1 to R^9 of the compounds I and the preferred representatives Ia to Ic corresponds to the description of the compound I already given in the introduction.
- The compounds of the formula I to be used according to the invention can be prepared by condensation in accordance with the equation

20
$$(R^{1})_{n}$$
 + R^{3} $-H_{2}O$ $(R^{1})_{n}$ H R^{3} R^{4} 25 $(R^{2})_{n}$ $(R^{2})_{n}$ $(R^{2})_{n}$ $(R^{2})_{n}$

where R^1 to R^4 have the meanings stated in claim 1.

The abovementioned condensation can be either base- or acid-catalyzed. Suitable catalysts are:

tertiary amines such as, for example, pyridine, morpholine,

triethylamine, triethanolamine; seconday amines such as, for example, piperidine, dimethylamine, diethylamine;

 $\mathrm{NH_3}$, $\mathrm{NaNH_2}$, $\mathrm{KNH_2}$, $\mathrm{NH_4OAc}$;

basic alumina, basic ion exchangers;

40 Na_2CO_3 , K_2CO_3 ;

acid catalysts such as, for example, glacial acetic acid, formic acid, propionic acid;

HC1, H_2SO_4 , HNO_3 ;

45 acid ion exchangers.

The amount of the catalysts is generally from 0.1 to 50 mol%, preferably 0.5 to 20 mol%, of the amount of aldehyde employed.

- The temperatures preferably employed are from 20 to 150°C, in particular 30 to 100°C, particularly preferably 40 to 80°C. No special conditions regarding the pressure are necessary; the reaction is generally carried out under atmospheric pressure.
- Solvents which can be employed are alcohols such as, for example, methanol, ethanol or isopropanol; aromatic compounds such as, for example, toluene or xylene; hydrocarbons, for example heptane or hexane; chlorinated hydrocarbons such as, for example, chloroform or dichloromethane; miglyol, tetrahydrofuran. However, the reaction can also be carried out without solvent.

It is also possible to prepare longer-chain esters starting from methyl or ethyl esters such as, for example, compound 1 in Table 2, by transesterification reactions in the presence of a basic catalyst.

Catalysts suitable for the transesterification are:

- basic alkali metal and alkaline earth metal salts, preferably those which are soluble neither in the starting materials nor in the products and which can easily be removed after the end of the reaction, particularly preferably: sodium, potassium or calcium carbonate or sodium hydrogencarbonate;
- alkaline earth metal oxides, preferably calcium or magnesium oxide and

basic zeolites.

35

The amount of the catalysts is generally from 1 to 80 mol%, preferably 5 to 50 mol%, of the amount of ester employed.

- The amount of alcohol employed must be at least equimolar to the amount of starting ester employed, for example compound 1 in Table 2. Amounts of from 200 to 500 mol% of the alcohol are preferably used.
- The methanol or ethanol which is formed is removed by distillation.

The temperatures preferably employed are from 50 to 250°C, in particular 60 to 150°C. No special conditions regarding the pressure are necessary; the reaction is generally carried out under atmospheric pressure.

5

Solvents which can be employed are inert, high-boiling compounds such as xylenes, but also toluene or mixtures of the alcohols employed with liquid, short-chain alkanes such as hexane and heptane. It is preferred to use no solvent in the alcohol employed.

The transesterification can be carried out either batchwise or continuously. In the continuous procedure, the reactants are preferably passed over a fixed bed of an insoluble base.

In the case where R³ ≠ R⁴, the compounds of the formula I according to the invention can, in principle, be in the form of their various geometric isomers, i.e. with a diene system having the Z,Z; Z,E; E,Z and/or E,E configuration. The preferred cosmetic sunscreens are the all-E and/or all-Z isomers, very particularly preferably the all-E isomers.

If $R^3 = R^4$, the C-C double bond between C-3 and C-4 (adjacent to 25 the diaryl system) can have the E and/or Z configuration, preferably the Z configuration.

The present invention also relates to cosmetic and pharmaceutical preparations which comprise from 0.1 to 10% by weight, preferably 1 to 7% by weight, based on the total amount of the cosmetic and pharmaceutical preparation, of one or more of the compounds of the formula I together with compounds which absorb in the UV-A and UV-B regions and are known per se for cosmetic and pharmaceutical preparations as sunscreens, where the compounds of the formula I are generally employed in a smaller amount than the UV-B-absorbing compounds.

The sunscreen-containing cosmetic and pharmaceutical preparations are, as a rule, based on a carrier which contains at least one oil phase. However, preparations with an exclusively aqueous basis are also possible on use of compounds having hydrophilic substituents. Accordingly, oils, oil-in-water and water-in-oil emulsions, creams and pastes, protective lipstick compositions or non-greasy gels are suitable.

Sunscreen products of these types can accordingly be in liquid, paste or solid form, for example as water-in-oil creams, oil-in-water creams and lotions, aerosol foam creams, gels, oils, wax pencils, powders, sprays or alcoholic-aqueous lotions.

5

The compounds of the formula I according to the invention can advantageously be incorporated into the aqueous or alcoholic-aqueous phase for preparation of the abovementioned sunscreens.

10

Examples of conventional cosmetic oil components are paraffin oil, glyceryl stearate, isopropyl myristate, diisopropyl adipate, cetylstearyl 2-ethylhexanoate, hydrogenated polyisobutene, petrolatum, caprylic acid/capric acid triglycerides, microcrystalline wax, lanolin and stearic acid.

Conventional cosmetic ancillary substances which may be suitable as additives are, for example, coemulsifiers, fats and waxes, 20 stabilizers, thickeners, biogenic active substances, film formers, fragrances, dyes, pearlizing agents, preservatives, pigments, electrolytes (e.g. magnesium sulfate) and pH regulators. Suitable and preferred coemulsifiers are known W/O as well as O/W emulsifiers such as polyglycerol esters, sorbitan 25 esters or partially esterified glycerides. Typical examples of fats are glycerides; waxes which may be mentioned are, inter alia, beeswax, paraffin wax or microwaxes, possibly combined with hydrophilic waxes. Stabilizers which can be employed are metal salts of fatty acids such as, for example, magnesium, aluminum 30 and/or zinc stearate. Examples of suitable thickeners are crosslinked polyacrylic acids and their derivatives, polysaccharides, in particular xanthan gum, guar-guar, agar-agar, alginates and tyloses, carboxymethylcellulose and hydroxyethylcellulose, also fatty alcohols, monoglycerides and 35 fatty acids, polyacrylates, polyvinyl alcohol and polyvinylpyrrolidone. Examples of biogenic active substances are plant extracts, protein hydrolysates and vitamin complexes. Examples of film formers which are in use are hydrocolloids such as chitosan, microcrystalline chitosan or quaternized chitosan, 40 polyvinylpyrrolidone, vinylpyrrolidone/ vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives and similar compounds. Examples of suitable preservatives are formaldehyde solution, p-hydroxybenzoate or sorbic acid. Examples of suitable pearlizing agents are glycol 45 distearic esters such as ethylene glycol distearate, but also fatty acids and fatty acid monoglycol esters. Dyes which can be

used are the substances suitable and approved for cosmetic

purposes, as tabulated, for example, in the publication "Kosmetische Färbemittel" of the Farbstoffkommission der Deutschen Forschungsgemeinschaft, published by Verlag Chemie, Weinheim, 1984. These dyes are normally employed in a 5 concentration of from 0.001 to 0.1% of the total weight of the mixture.

The total content of ancillary substances and additives can be from 1 to 80, preferably 6 to 40, % by weight, and the nonaqueous content ("active substance") can be from 20 to 80, preferably 30 to 70, % by weight, based on the compositions. The compositions can be produced in a manner known per se, i.e. for example by hot, cold, hot-hot/cold or PIT emulsification. This is a purely mechanical process; no chemical reaction takes place.

Finally, it is also possible to use other substances which absorb in the UV region and are known per se as long as they are stable in the complete system of the combination of UV filters to be used according to the invention.

Most of the sunscreens in the cosmetic and pharmaceutical preparations used for protecting the human epidermis consist of compounds which absorb UV light in the UV-B region, i.e. in the region from 280 to 320 nm. The content of UV-A absorbers to be used according to the invention is, for example, from 10 to 90%, preferably 20 to 50%, of the total weight of UV-B- and UV-A-absorbing substances.

30 Any UV-A and UV-B filter substances are suitable as UV filter substances which are used in combination with the compounds of the formula I to be used according to the invention. Examples which may be mentioned are:

35 Table 2:

| | No. | Substance | CAS No. (=acid) |
|----|-----|---|-----------------|
| | 1 | 4-Aminobenzoic acid | 150-13-0 |
| 40 | 2 | 3-(4-Trimethylammonio)benzylidenebornan-2-one methyl sulfate | 52793-97-2 |
| | 3 | 3,3,5-Trimethylcyclohexyl salicylate (homosalate) | 118-56-9 |
| 45 | 4 | 2-Hydroxy-4-methoxybenzophenone (oxybenzone) | 131-57-7 |
| | 5 | 2-Phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts | 27503-81-7 |

| | No. | Substance | CAS No. (=acid) |
|----|-----|---|-----------------|
| 5 | 6 | 3,3'-(1,4-Phenylenedimethine)bis(7,7-dimethy1-2-oxobicyclo[2.2.1]heptane-1-methane-sulfonic acid) and its salts | 90457-82-2 |
| | 7 | Polyethoxyethyl 4-bis(polyethoxy)aminobenzoate | 113010-52-9 |
| | 8 | 2-Ethylhexyl 4-dimethylaminobenzoate | 21245-02-3 |
| | 9 | 2-Ethylhexyl salicylate | 118-60-5 |
| 10 | 10 | Isoamyl 4-methoxycinnamate | 71617-10-2 |
| 10 | 11 | 2-Ethylhexyl 4-methoxycinnamate | 5466-77-3 |
| | 12 | 2-Hydroxy-4-methoxybenzophenone-5-sulfonic acid (sulisobenzone) and the sodium salt | 4065-45-6 |
| | 13 | 3-(4'-Methylbenzylidene)bornan-2-one | 36861-47-9 |
| 15 | 14 | 3-Benzylidenebornan-2-one | 15087-24-8 |
| | 15 | 1-(4'-Isopropylphenyl)-3-phenylpropane-1,3-dione | 63260-25-9 |
| 20 | 16 | 4-Isopropylbenzyl salicylate | 94134-93-7 |
| | 17 | 2,4,6-Tri(o-2-ethylhexoxycarbonyl-anilino)-1,3,5-triazine | 88122-99-0 |
| | 18 | 3-(4-Imidazolyl)acrylic acid and its ethyl ester | 104-98-3 |
| | 19 | Ethyl 2-cyano-3,3-diphenylacrylate | 5232-99-5 |
| ٥. | 20 | 2-Ethylhexyl 2-cyano-3,3-diphenylacrylate | 6197-30-4 |
| 25 | 21 | Menthyl o-aminobenzoate or: 5-methyl-2-(1-methylethyl)cyclohexyl 2-aminobenzoate | 134-09-8 |
| | 22 | Glyceryl p-aminobenzoate or: 4-aminobenzoic acid 1-glyceryl ester | 136-44-7 |
| 30 | 23 | 2,2'-Dihydroxy-4-methoxybenzophenone (dioxybenzone) | 131-53-3 |
| | 24 | 2-Hydroxy-4-methoxy-4-methylbenzophenone (mexenone) | 1641-17-4 |
| | 25 | Triethanolamine salicylate | 2174-16-5 |
| 35 | 26 | Dimethoxyphenylglyoxalic acid or: sodium 3,4-dimethoxyphenylglyoxalate | 4732-70-1 |
| | 27 | 3-(4'-Sulfobenzylidene)bornan-2-one and its salts | 56039-58-8 |
| | 28 | 4-tert-Butyl-4'-methoxydibenzoylmethane | 70356-09-1 |
| 40 | 29 | 2,2',4,4'-Tetrahydroxybenzophenone | 131-55-5 |

Finally, mention may also be made of micronized pigments such as titanium dioxide and zinc oxide.

To protect human hair from UV rays, the sunscreens of the formula I according to the invention can be incorporated into shampoos, lotions, gels, hair sprays, aerosol foam creams or emulsions in concentrations of from 0.1 to 10% by weight, preferably 1 to 7% 5 by weight. The particular formulations can be used inter alia for washing, coloring and styling the hair.

Compounds of the formula I which are particularly preferred for this purpose are those in which the substituents R^3 and/or R^4 are cationic radicals, such as, for example, compound 2 in Table 3.

The compounds to be used according to the invention as a rule have a particularly high absorbance in the region of UV-A radiation with a sharp band structure. They are furthermore readily soluble in aqueous or alcoholic-aqueous systems and can thus easily be incorporated into the aqueous phase of cosmetic formulations. The emulsions prepared using the compounds I show particularly high stability, the compounds I themselves show high photostability, and the preparations produced with I have a pleasant feel on the skin.

The UV filter action of the compounds of the formula I according to the invention can also be utilized for stabilizing active and ancillary substances in cosmetic and pharmaceutical formulations.

The invention also relates to the compounds of the formula I for use as a medicament and to pharmaceutical compositions for the preventive treatment of inflammation and allergies of the skin, 30 and for preventing certain types of skin cancer, which comprise an effective amount of at least one compound of the formula I as active substance.

The pharmaceutical composition according to the invention can be administered orally or topically. For oral administration, the pharmaceutical composition is in the form of, inter alia, pastilles, gelatine capsules, coated tablets, as a syrup, solution, emulsion or suspension. The pharmaceutical compositions are used topically for example as an ointment, cream, gel, spray, solution or lotion.

Examples:

I. Preparation

Example 1:

10
$$\xrightarrow{\text{OMe}}$$
 OMe $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{SO}_3\text{H}}$ $\xrightarrow{\text{SO}_3\text{H}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{OMe}}$ $\xrightarrow{\text{SO}_3\text{H}}$ \xrightarrow

0.1 mol of dimethyl malonate (1) was heated with 0.2 mol of 2-hydroxyethylsulfonic acid (2) in xylene. The water of reaction was continuously removed azeotropically. After all of the water of reaction had been removed, the organic phase was washed with 2 n NaOH, and the desired product (3) was crystallized from the aqueous phase by acidification with $\rm H_2SO_4$ to pH = 2. Yield: 75% of theory.

25 Example 2:

0.11 mol of compound 3 from Example 1 was added to 0.1 mol of β -phenylcinnamaldehyde (4) in 100 ml of xylene. After 0.01 mol of piperidine had been added, the reaction mixture was refluxed for 40 4 h. The mixture was then cooled and washed with 2 n NaOH, and the aqueous phase, following phase separation, was adjusted to pH = 2, during which the product (5) precipitated out. Yield: 82% of theory. Purity: > 98% (HPLC). $E^1_1 = 650$, $\lambda_{max} = 336$ nm.

 ${f 45}$ The compounds listed in Table 3 were prepared as in Example 2.

Table 3:

| | No. | | E ¹ 1 | λ_{max} |
|----|-----|--|------------------|-----------------|
| 10 | 1 | Ph CN Ph O O O O O O O O O O O O O O O O O O | 680 | 354 |
| 15 | 2 | Ph | 450 | 330 |
| 20 | 3 | Ph O O O O O O O O O O O O O O O O O O O | 600 | 335 |
| 25 | | OCH ₃ | | |

The compounds in Tables 4 and 5 can be prepared as in Example 2or as described in the general section.

Table 4:

$$(R^{1})_{n} \xrightarrow{H} COOR^{5}$$

$$COOR^{6}$$

$$(R^{2})_{n}$$

$$R^{5} = R^{6}$$

| 40 | No. | $R^5 = R^6$ | R ¹ | R ² | n | Posi- tion |
|----|-----|--|-----------------|-----------------|---|---------------|
| | 1) | -(CH ₂) ₂ -SO ₃ Na | Н | Н | 1 | - |
| 45 | 2) | -(CH ₂) ₃ -SO ₃ Na | Н | Н | 1 | - |
| | 3) | - (CH ₂) ₂ -SO ₃ Na | CH ₃ | CH ₃ | 1 | para |
| 73 | 4) | -(CH ₂) ₃ -SO ₃ Na | CH ₃ | CH ₃ | 1 | para |
| | 5) | [-(CH ₂) ₂ -O-] ₃ -CH ₃ | CH ₃ | CH ₃ | 1 | para |

| | No. | R ⁵ = R ⁶ | R ¹ | R ² | n | Posi- tion |
|----|-----|---|--------------------|--------------------|---|---------------|
| 5 | 6) | $-(CH_2)_2-SO_3Na$ | CH ₃ O | CH ₃ O | 1 | para |
| | 7) | -(CH2)3-SO3Na | CH ₃ O | CH ₃ O | 1 | para |
| כ | 8) | $[-(CH_2)_2-O-]_3-CH_3$ | CH ₃ O | CH ₃ O | 1 | para |
| | 9) | - (CH ₂) ₂ -SO ₃ Na | SO₃Na | SO₃Na | 1 | para |
| | 10) | - (CH ₂) ₃ -SO ₃ Na | SO₃Na | SO ₃ Na | 1 | para |
| | 11) | [-(CH2)2-O-]3-CH3 | SO ₃ Na | SO ₃ Na | 1 | para |
| 10 | 12) | - (CH ₂) ₂ -SO ₃ Na | COONa | COONa | 1 | para |
| | 13) | - (CH ₂) ₃ -SO ₃ Na | COONa | COONa | 1 | para |
| | 14) | [-(CH2)2-O-]3-CH3 | COONa | COONa | 1 | para |

Table 5:

$$(R^{1})_{n} \xrightarrow{H} CONR^{5}R^{6}$$

$$CONR^{5}R^{6}$$

$$R^{5} \neq R^{6}$$

| 25 | No. | R ⁵ | R ⁶ | R ¹ | R ² | n | Posi- tion |
|-----|-----|----------------|--|-------------------|--------------------|---|---------------|
| | 1) | Н | -(CH2)3-N(CH3)3+ Cl- | Н | Н | 1 | - |
| | 2) | Н | [-(CH2)2-O-]3-CH3 | Н | Н | 1 | - |
| | 3) | Н | $[-(CH_2)_2-O-]_4-CH_3$ | Н | Н | 1 | - |
| 30 | 4) | Н | [-(CH ₂) ₂ -O-] ₅ -CH ₃ | Н | н | 1 | _ |
| | 5) | Н | -(CH2)3-N(CH3)3+Cl- | CH ₃ | CH ₃ | 1 | para |
| | 6) | Н | $[-(CH_2)_2-O-]_3-CH_3$ | CH ₃ | CH ₃ | 1 | para |
| | 7) | Н | $[-(CH_2)_2-O-]_4-CH_3$ | CH ₃ | CH ₃ | 1 | para |
| 2.5 | 8) | Н | [-(CH2)2-O-]5-CH3 | CH ₃ | CH ₃ | 1 | para |
| 35 | 9) | Н | -(CH2)3-N(CH3)3+ C1- | CH ₃ O | CH ₃ O | 1 | para |
| | 10) | Н | $[-(CH_2)_2-O-]_3-CH_3$ | CH ₃ O | CH ₃ O | 1 | para |
| | 11) | Н | $[-(CH_2)_2-O-]_4-CH_3$ | CH ₃ O | CH ₃ O | 1 | para |
| | 12) | Н | [-(CH2)2-O-]5-CH3 | CH ₃ O | CH ₃ O | 1 | para |
| 40 | 13) | Н | -(CH2)3-N(CH3)3+C1- | S0₃Na | SO ₃ Na | 1 | para |
| | 14) | Н | $[-(CH_2)_2-O-]_3-CH_3$ | S0₃Na | SO ₃ Na | 1 | para |
| | 15) | Н | $[-(CH_2)_2-O-]_4-CH_3$ | S0₃Na | SO ₃ Na | 1 | para |
| | 16) | Н | [-(CH2)2-O-]5-CH3 | S0₃Na | SO₃Na | 1 | para |
| 45 | 17) | Н | -(CH2)3-N(CH3)3+Cl- | C00Na | COONa | 1 | para |
| | 18) | Н | [-(CH2)2-O-]3-CH3 | COONa | COONa | 1 | para |

| No. | R ⁵ | R ⁶ | R ¹ | R ² | n | Posi- tion |
|-----|----------------|--|----------------|----------------|---|---------------|
| 19) | Н | $[-(CH_2)_2-O-]_4-CH_3$ | COONa | COONa | 1 | para |
| 20) | Н | [-(CH ₂) ₂ -O-] ₅ -CH ₃ | COONa | COONa | 1 | para |

Example 4

10 Standardized method for photostability determination (Suntest)

A 5% by weight alcoholic-aqueous solution of the sunscreen to be tested is applied, using an Eppendorf pipette (20 μ l), to the milled area on a small glass plate. Owing to the presence of the alcohol, the solution is distributed uniformly on the roughened glass surface. The amount applied corresponds to the amount of sunscreen required to obtain an average sun protection factor in suncreams. In the test, 4 glass plates are irradiated each time. The evaporation time and the irradiation each last for 30

- 20 minutes. The glass plates are cooled slightly during the irradiation by a water cooling system located at the base of the Suntest apparatus. The temperature inside the Suntest apparatus during the irradiation is 40°C. After the samples have been irradiated, they are washed with ethanol into a dark 50 ml
- graduated flask and measured using a photometer. The blank samples are applied in the same way to glass plates and evaporated at room temperature for 30 minutes. Like the other samples, they are washed off with ethanol and diluted to 100 ml and measured.

30

Photostability comparative tests:

1.

35

40

Photostability: 98%

Photostability: < 30%

General method for preparing emulsions for cosmetic purposes

All of the oil-soluble ingredients are heated to 85°C in a stirred vessel. When all the ingredients have melted or are present as liquid phase, the aqueous phase, which comprises, in the dissolved state, the 4,4-diarylbutadienes of the formula I according to the invention, possibly in the form of their salts, is incorporated by homogenization. The emulsion is cooled to about 40°C with stirring, is perfumed and homogenized, and is then cooled to 25°C while stirring continuously.

Preparations

Example 5

15

Lip care composition

Mass content

(% by weight)

20

ad 100 eucerinum anhydricum

10.00 glycerol

10.00 titanium dioxide

5.00 compound from Example 2

25 8.00 octyl methoxycinnamate

5.00 zinc oxide

4.00 castor oil

4.00 pentaerythrityl stearate/caprate/caprylate/adipate

3.00 glyceryl stearate SE

30 2.00 beeswax

2.00 microcrystalline wax

2.00 quaternium-18 bentonite

1.50 PEG-45/dodecyl glycol copolymer

35 Example 6

Lip care composition

Mass content

40 (% by weight)

ad 100 eucerinum anhydricum

10.00 glycerol

10.00 titanium dioxide

45 5.00 compound No. 1 in Table 3

8.00 octyl methoxycinnamate

5.00 zinc oxide

```
4.00
            castor oil
   4.00
            pentaerythrityl stearate/caprate/caprylate/adipate
   3.00
            glyceryl stearate SE
   2.00
            beeswax
 5 2.00
            microcrystalline wax
   2.00
            quaternium-18 bentonite
   1.50
            PEG-45/dodecyl glycol copolymer
   Example 7
10
   Sunblocker composition with micropigments
   Mass content
   (% by weight)
   ad 100
            water
   10.00
            octyl methoxycinnamate
            PEG-7 hydrogenated castor oil
   6.00
   6.00
            titanium dioxide
   5.00
            compound from Example 2
20 5.00
            mineral oil
   5.00
            isoamyl p-methoxycinnamate
   5.00
            propylene glycol
   3.00
            jojoba oil
   3.00
            4-methylbenzylidenecamphor
25 2.00
            PEG-45/dodecyl glycol copolymer
   1.00
            dimethicone
   0.50
            PEG-40 hydrogenated castor oil
   0.50
            tocopheryl acetate
   0.50
            phenoxyethanol
30 0.20
            EDTA
   Example 8
   Sunblocker composition with micropigments
35
   Mass content
   (% by weight)
   ad 100
            water
40 10.00
            octyl methoxycinnamate
   6.00
            PEG-7 hydrogenated castor oil
   6.00
            titanium dioxide
   5.00
            compound No. 1 in Table 3
   5.00
            mineral oil
45 5.00
            isoamyl p-methoxycinnamate
   5.00
            propylene glycol
   3.00
            jojoba oil
```

```
3.00
            4-methylbenzylidenecamphor
   2.00
            PEG-45/dodecyl glycol copolymer
   1.00
            dimethicone
   0.50
            PEG-40 hydrogenated castor oil
 5 0.50
            tocopheryl acetate
   0.50
            phenoxyethanol
   0.20
            EDTA
   Example 9
10
   Non-greasy gel
   Mass content
   (% by weight)
15
   ad 100
            water
   8.00
            octyl methoxycinnamate
   7.00
            titanium dioxide
   5.00
            compound from Example 2
20 5.00
            glycerol
   5.00
            PEG-25 PABA
   1.00
            4-methylbenzylidenecamphor
   0.40
            acrylate C10-C30 alkyl acrylate crosspolymer
   0.30
            imidazolidinylurea
25 0.25
            hydroxyethylcellulose
   0.25
            sodium methylparaben
   0.20
            disodium EDTA
   0.15
            fragrance
   0.15
            sodium propylparaben
30 0.10
            sodium hydroxide
   Example 10
   Non-greasy gel
35
   Mass content
   (% by weight)
   ad 100
            water
40 8.00
            octyl methoxycinnamate
   7.00
            titanium dioxide
   5.00
            compound No. 1 in Table 3
   5.00
            glycerol
   5.00
            PEG-25 PABA
45 1.00
            4-methylbenzylidenecamphor
            acrylate C10-C30 alkyl acrylate crosspolymer
   0.40
   0.30
            imidazolidinylurea
```

0.25 hydroxyethylcellulose
0.25 sodium methylparaben
0.20 disodium EDTA
0.15 fragrance
5 0.15 sodium propylparaben
0.10 sodium hydroxide

Example 11

10 Suncream (SPF 20)

Mass content (% by weight)

15 ad 100 water 8.00 octvl methoxycinnamate 8.00 titanium dioxide 6.00 PEG-7 hydrogenated castor oil 5.00 compound from Example 2 20 6.00 mineral oil 5.00 zinc oxide 5.00 isopropyl palmitate 5.00 imidazolidinylurea 3.00 jojoba oil **25** 2.00 PEG-45/dodecyl glycol copolymer 1.00 4-methylbenzylidenecamphor 0.60 magnesium stearate 0.50 tocopheryl acetate 0.25 methylparaben 30 0.20 disodium EDTA 0.15 propylparaben

Example 12

35 Suncream (SPF 20)

Mass content (% by weight)

40 ad 100 water 8.00 octyl methoxycinnamate 8.00 titanium dioxide 6.00 PEG-7 hydrogenated castor oil 5.00 compound No. 1 in Table 3 **45** 6.00 mineral oil 5.00 zinc oxide 5.00 isopropyl palmitate

```
5.00
           imidazolidinylurea
   3.00
           jojoba oil
   2.00
           PEG-45/dodecyl glycol copolymer
   1.00
           4-methylbenzylidenecamphor
 5 0.60
           magnesium stearate
  0.50
          tocopheryl acetate
  0.25
           methylparaben
  0.20
           disodium EDTA
   0.15
          propylparaben
10
  Example 13
```

Water-resistant suncream

15 Mass content (% by weight)

| | ad 100 | water |
|----|--------|---------------------------------|
| | 8.00 | octyl methoxycinnamate |
| 20 | 5.00 | PEG-7 hydrogenated castor oil |
| | 5.00 | propylene glycol |
| | 4.00 | isopropyl palmitate |
| | 4.00 | caprylic/capric triglyceride |
| | 5.00 | compound from Example 2 |
| 25 | 4.00 | glycerol |
| | 3.00 | jojoba oil |
| | 2.00 | 4-methylbenzylidenecamphor |
| | 2.00 | titanium dioxide |
| | 1.50 | PEG-45/dodecyl glycol copolymer |
| 30 | 1.50 | dimethicone |
| | 0.70 | magnesium sulfate |
| | 0.50 | magnesium stearate |
| | 0.15 | fragrance |
| | | |

35 Example 14

Water-resistant suncream

Mass content **40** (% by weight)

ad 100 water

```
8.00
            octyl methoxycinnamate
   5.00
            PEG-7 hydrogenated castor oil
   5.00
            propylene glycol
   4.00
            isopropyl palmitate
5 4.00
            caprylic/capric triglyceride
   5.00
            compound No. 1 in Table 3
   4.00
            glycerol
   3.00
            jojoba oil
   2.00
            4-methylbenzylidenecamphor
10 2.00
            titanium dioxide
   1.50
            PEG-45/dodecyl glycol copolymer
   1.50
            dimethicone
   0.70
            magnesium sulfate
   0.50
            magnesium stearate
15 0.15
            fragrance
   Example 15
   Sunmilk (SPF 6)
20
   Mass content
   (% by weight)
   ad 100
           water
25 10.00
            mineral oil
   6.00
            PEG-7 hydrogenated castor oil
   5.00
            isopropyl palmitate
   3.50
            octyl methoxycinnamate
   5.00
            compound from Example 2
30 3.00
            caprylic/capric triglyceride
   3.00
            jojoba oil
   2.00
            PEG-45/dodecyl glycol copolymer
   0.70
            magnesium sulfate
   0.60
            magnesium stearate
35 0.50
            tocopheryl acetate
   0.30
            glycerol
   0.25
            methylparaben
   0.15
            propylparaben
   0.05
            tocopherol
40
   Example 16
   Sunmilk (SPF 6)
45 Mass content
   (% by weight)
```

| | ad 100 | water |
|----|--------|---------------------------------|
| | 10.00 | mineral oil |
| | 6.00 | PEG-7 hydrogenated castor oil |
| | 5.00 | isopropyl palmitate |
| 5 | 3.50 | octyl methoxycinnamate |
| | 5.00 | compound No. 1 in Table 3 |
| | 3.00 | caprylic/capric triglyceride |
| | 3.00 | jojoba oil |
| | 2.00 | PEG-45/dodecyl glycol copolymer |
| 10 | 0.70 | magnesium sulfate |
| | 0.60 | magnesium sterarate |
| | 0.50 | tocopheryl acetate |
| | 0.30 | glycerol |
| | 0.25 | methylparaben |
| 15 | 0.15 | propylparaben |
| | 0.05 | tocopherol |

"Comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not 20 preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

 $_{5}$ 1. The use of 4,4-diarylbutadienes of the formula I,

$$(R^1)_n \xrightarrow{H} R^3$$

$$(R^2)_n$$

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

 R^1 and R^2

25

40

hydrogen, C_1 - C_{20} -alkyl, C_2 - C_{10} -alkenyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkenyl, C_1 - C_{12} -alkoxy, C_1 - C_{20} -alkoxycarbonyl, C_1 - C_{12} -alkylamino, C_1 - C_{12} -dialkylamino, aryl, hetaryl, unsubstituted or substituted substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

- R³ hydrogen, COOR⁵, COR⁵, CONR⁵R⁶, CN;
 - R4 COOR6, COR6, CONR5R6;
- 35 R⁵ hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-PO₃Y, C_1-C_6 -alkylene-N(R⁸)₃+ A⁻;
 - R^6 [X]_o- R^7 , C_1 - C_6 -alkylene- SO_3 Y, C_1 - C_6 -alkylene- PO_3 Y, C_1 - C_6 -alkylene- $N(R^8)_3$ + A-;

 $X = -CH_2-CH_2-Z-, -CH_2-CH_2-CH_2-Z-, -CH(CH_3)-CH_2-Z-, -CH_2-CH_2-CH_2-CH_2-Z-, -CH_2-CH(CH_2-CH_3)-Z-;$

A Cl, Br, I, SO₄R⁹;

Y hydrogen, Na⁺, K⁺, Mg²⁺, Ca²⁺, Li⁺, Al³⁺, N(R⁸)₄+;

Z O, NH;

R⁷ and R⁸ hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-acyl;

R⁹ hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl;

n 1 to 3;

o 1 to 150

as water-soluble photostable UV filters in cosmetic and pharmaceutical preparations for protecting the human skin or human hair from the sun's rays, alone or together with compounds which absorb in the UV region and are known per se for cosmetic and pharmaceutical preparations.

- 2. The use of compounds of the formula I as claimed in claim 1 as water-soluble photostable UV-A filters.
- 3. The use of compounds of the formula I as claimed in claims 1 or 2 as water-soluble UV stabilizers in cosmetic and pharmaceutical formulations.
- 4. A suncreen-containing cosmetic or pharmaceutical preparation for protecting the human epidermis or human hair from UV light in the range from 280 to 400 nm, which comprises, in a cosmetically or pharmaceutically suitable carrier, alone or together with compounds which absorb in the UV region and are known per se for cosmetic and pharmaceutical preparations, amounts, which are effective as photostable UV filters, of compounds of the formula I

$$(R^1)_n$$
 H
 R^3
 R^4
 $(R^2)_n$



where the variables have the meanings stated in claim 1.

5. A 4,4-diarylbutadiene of the formula I,

5

10

$$(R^1)_n \xrightarrow{H} R^3$$

$$(R^2)_n$$

where the diene system has the Z,Z; Z,E; E,Z or E,E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

 R^1 and R^2

hydrogen, C_1 - C_{20} -alkyl, C_2 - C_{10} -alkenyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkenyl, C_1 - C_{12} -alkoxy, C_1 - C_{20} -alkoxycarbonyl, C_1 - C_{12} -alkylamino, C_1 - C_{12} -dialkylamino, aryl, hetaryl, unsubstituted or substituted substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

- R³ hydrogen, COOR⁵, COR⁵, CONR⁵R⁶, CN;
- R^4 COOR⁶, COR⁶, CONR⁵R⁶;
 - R⁵ hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-S0₃Y, C_1-C_6 -alkylene-P0₃Y, C_1-C_6 -alkylene-N(R⁸)₃+ A⁻;

35 $R^{6} \quad [X]_{o}-R^{7}, C_{1}-C_{6}-alkylene-SO_{3}Y, C_{1}-C_{6}-alkylene-PO_{3}Y, \\ C_{1}-C_{6}-alkylene-N(R^{8})_{3}+A^{-};$

A C1, Br, I, SO₄R⁹;

Y hydrogen, Na⁺, K⁺, Mg²⁺, Ca²⁺, Li⁺, Al³⁺, N(R⁸)₄⁺; 45

Z O, NH;

R⁷ and R⁸ hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₁-C₆-acyl;

R⁹ hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl;

n 1 to 3;

o 1 to 150

6. A 4,4-diarylbutadiene of the formula I as claimed in claim 5, hereinafter referred to as Ia

$$(R^1)_n$$
 H
 R^3
 R^4
 $(R^2)_n$

where the diene system has the Z, Z; Z, E; E, Z or E, E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

R¹ and R²

hydrogen, C_1 - C_8 -alkyl, C_1 - C_8 -alkoxy,

substituents which confer solubility in water and are selected from the group consisting of carboxylate, sulfonate or ammonium radicals;

R³ COOR⁵, CONR⁵R⁶, CN;

R⁴ COOR⁶, CONR⁵R⁶;

 R^5 hydrogen, $[X]_0-R^7$, C_1-C_6 -alkylene-SO₃Y, C_1-C_6 -alkylene-N(R^8)₃⁺A⁻;

 R^6 [X]₀- R^7 , C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R^8)₃⁺A⁻;

X -CH₂-CH₂-O-, -CH₂-CH₂-CH₂-O-, -CH(CH₃)-CH₂-O-;

A CI, Br, I, SO₄R⁹;

Y hydrogen, Na^+ , K^+ , Mg^{2+} , Ca^{2+} , Li^+ , Al^{3+} , $N(R^8)_4^+$;

R⁷ to R⁹ hydrogen, C₁-C₃-alkyl;

n 1 to 3;



- o 1 to 50.
- 7. A 4,4-diarylbutadiene of the formula I as claimed in claim 5, hereinafter referred to as Ib

$$R^1$$
 R^2
 R^4
 R^4
 R^4

where the diene system has the Z, Z; Z, E; E, Z or E, E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

R¹ and R²

hydrogen, C_1 - C_8 -alkyl, C_1 - C_8 -alkoxy;

R³ COOR⁵, CONR⁵R⁶, CN;

R⁴ COOR⁶, CONR⁵R⁶;

 R^5 hydrogen [X]₀- R^7 , C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R^8)₃+A⁻;

 R^6 [X]₀- R^7 , C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R^8)₃+A⁻;

X -CH₂-CH₂-O-, -CH₂-CH₂-CH₂-O-, -CH(CH₃)-CH₂-O-;

A CI, Br, I, SO₄R⁹;

Y hydrogen, Na⁺, K⁺, Mg²⁺, Ca²⁺, Li⁺, Al³⁺, N(R⁸)₄⁺;

R⁷ to R⁹ hydrogen, C₁-C₃-alkyl;

- o 1 to 50.
- 8. A 4,4-diarylbutadiene of the formula I as claimed in claim 5, hereinafter referred to as Ic



$$R^1$$
 H
 R^3
 R^4
 R^4

where the diene system has the Z, Z; Z, E; E, Z or E, E configuration or a mixture thereof, and where the variables independently of one another have the following meanings:

R¹ and R²

hydrogen, C₁-C₈-alkyl, C₁-C₈-alkoxy,

R³ COOR⁵, CONR⁵R⁶, CN;

R⁴ COOR⁶, CONR⁵R⁶:

 R^5 hydrogen [X]₀- R^7 , C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R^8)₃+A⁻;

 R^6 [X]₀- R^7 , C₁-C₆-alkylene-SO₃Y, C₁-C₆-alkylene-N(R^8)₃+A⁻;

X -CH₂-CH₂-O-, -CH₂-CH₂-CH₂-O-, -CH(CH₃)-CH₂-O-;

A Cl, Br, I, SO₄R⁹;

Y hydrogen, Na⁺, K⁺, Mg²⁺, Ca²⁺, Li⁺, Al³⁺, N(R⁸)₄⁺;

R⁷ to R⁹ hydrogen, C₁-C₃-alkyl;

o 1 to 50.

9. A pharmaceutical preparation which comprises an effective amount of at least one compound of the formula I as set forth in claim 4.

DATED this 4th day of March 2002 **BASF AKTIENGESELLSCHAFT**

WATERMARK PATENT & TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA

CJH/TAP/VRH P6154AU00

